Significant Reduction in the Incidence of Genital Warts in Young Men 5 Years Into the Danish Human Papillomavirus Vaccination Program for Girls and Women
BACKGROUND:
Denmark
introduced the quadrivalent human papillomavirus vaccine into the vaccination
program for 12- to 15-year-old girls in 2008 to 2009. In 2012, the program was
supplemented with a catch-up program for women aged up to 27 years. We
evaluated the effectiveness of the Danish vaccination program on the nationwide
incidence of genital warts (GWs), after the second catch-up by including
information on both hospital treatments and on self-administered treatment with
podophyllotoxin. Genital wart incidence was investigated in both sexes;
however, the main focus was on potential herd protection of men.
METHODS:
Incident
cases of GWs were identified from the Danish National Patient Register and
through redemptions of prescription for podophyllotoxin in the Danish National
Prescription Registry in 2006 to 2013. Age-specific incidence rates (IRs) were
assessed, and estimated annual percentage change (EAPC) was calculated by
Poisson regression.
RESULTS:
Genital
wart incidence was either stable or increased in both sexes in 2006 to 2008.
After introduction of the vaccination program, GW incidence decreased
significantly in women aged 12 to 35 years and men aged 12 to 29 years, with
rapid decrease among 16- to 17-year-olds (IRwomen, from 1071 to 58 per 100,000
person-years [EAPC, -55.1%; 95% confidence interval, -58.7 to-51.2]; IRmen,
from 365 to 77 per 100,000 person-years [EAPC, -36.6%; 95% confidence interval,
-40.5 to -32.5] in 2008-2013).
CONCLUSIONS:
We
found a significantly decreasing incidence of GWs in women up to 35 years of
age after the start of the human papillomavirus vaccination program. A similar
pattern was observed for men aged 12 to 29 years, indicating substantial herd
protection.
- 1From the *Virus, Lifestyle and Genes, Danish Cancer Society Research Center, Copenhagen, Denmark; †Statistics, Bioinformatics and Registry, Danish Cancer Society Research Center, Copenhagen, Denmark; and ‡Department of Gynecology, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark.
- Sex Transm Dis. 2016 Apr;43(4):238-42. doi: 10.1097/OLQ.0000000000000418.
No comments:
Post a Comment